Re-appointment of Mr. Davuluri Saharsh Rao (DIN: 02753145), as Whole Time Director, designated as Vice Chairman & Managing Director
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Neuland Laboratories reported audited FY25 (year ended March 31, 2025) results with consolidated revenue of Rs. 1,497.3 crores, down from Rs. 1,571.1 crores in FY24. Consolidated profit after tax stood at Rs. 260.1 crores vs Rs. 300.1 crores, with EPS at Rs. 202.74 vs Rs. 233.89. Statutory auditors MSKA & Associates issued an unmodified opinion. The board recommended a final dividend of Rs. 12 per share (120% on face value of Rs. 10), subject to shareholder approval at the 41st AGM on July 30, 2025. Mr. Davuluri Saharsh Rao was re-appointed as Whole Time Director designated Vice Chairman & Managing Director for a fresh 5-year term from June 1, 2025. The company also appointed P.S. Rao & Associates as secretarial auditors for 5 years (FY26–FY30).
Core operations saw a revenue and profit dip year-on-year, though headline profit was lifted by a Rs. 76.4 crore exceptional gain from transferring an investment property via perpetual lease. The 120% dividend signals healthy cash flows and shareholder rewards despite operational softness. Re-appointment of a promoter family member (son of the Executive Chairman and brother of the CEO) ensures leadership continuity.